Trial Profile
A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Sifalimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 08 Nov 2017 Results of a post-hoc analysis assessing the influence of smoking on cutaneous manifestation severity in patients of this and another trial (NCT01438489) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 17 Jun 2017 Results of gene expression signature analysis of blood samlples from adult patients enrolled in two phase IIb studies including this study presented at the 18th Annual Congress of the European League Against Rheumatism
- 23 Mar 2016 Results published in the Annals of the Rheumatic Diseases